Karyopharm Therapeutics Inc (NASDAQ:KPTI) – Jefferies Financial Group cut their Q3 2018 EPS estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, August 8th. Jefferies Financial Group analyst M. Raycroft now forecasts that the company will post earnings per share of ($0.80) for the quarter, down from their prior forecast of ($0.71). Jefferies Financial Group currently has a “Buy” rating on the stock. Jefferies Financial Group also issued estimates for Karyopharm Therapeutics’ Q4 2018 earnings at ($0.84) EPS, FY2019 earnings at ($2.93) EPS, FY2020 earnings at ($1.27) EPS, FY2021 earnings at ($0.96) EPS and FY2022 earnings at $0.48 EPS.
Several other brokerages also recently commented on KPTI. HC Wainwright reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, June 15th. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Monday, April 30th. Zacks Investment Research raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research note on Wednesday, July 25th. Wedbush downgraded Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $20.00 to $19.00 in a research note on Thursday, May 24th. Finally, ValuEngine raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $22.90.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, August 7th. The company reported ($0.60) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.81) by $0.21. The company had revenue of $19.89 million for the quarter, compared to analyst estimates of $5.97 million.
In other news, CEO Michael Kauffman sold 10,000 shares of the business’s stock in a transaction dated Friday, May 18th. The stock was sold at an average price of $19.39, for a total value of $193,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction dated Monday, July 9th. The shares were sold at an average price of $18.72, for a total value of $234,000.00. Following the completion of the transaction, the insider now directly owns 726,010 shares in the company, valued at $13,590,907.20. The disclosure for this sale can be found here. Insiders sold a total of 385,913 shares of company stock worth $7,203,596 over the last three months. 13.26% of the stock is owned by company insiders.
Hedge funds have recently bought and sold shares of the stock. Northern Trust Corp raised its stake in Karyopharm Therapeutics by 3.0% during the 1st quarter. Northern Trust Corp now owns 397,294 shares of the company’s stock worth $5,331,000 after buying an additional 11,577 shares during the period. venBio Select Advisor LLC acquired a new position in Karyopharm Therapeutics during the 1st quarter worth approximately $7,524,000. Millennium Management LLC raised its stake in Karyopharm Therapeutics by 17.8% during the 4th quarter. Millennium Management LLC now owns 436,836 shares of the company’s stock worth $4,194,000 after buying an additional 65,920 shares during the period. Prudential Financial Inc. raised its stake in Karyopharm Therapeutics by 259.3% during the 1st quarter. Prudential Financial Inc. now owns 68,736 shares of the company’s stock worth $923,000 after buying an additional 49,606 shares during the period. Finally, Deutsche Bank AG raised its stake in Karyopharm Therapeutics by 16.1% during the 4th quarter. Deutsche Bank AG now owns 188,373 shares of the company’s stock worth $1,806,000 after buying an additional 26,108 shares during the period. 64.78% of the stock is currently owned by institutional investors and hedge funds.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Recommended Story: Penny Stocks
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.